top of page

Liver transplantation

For patients with end-stage liver disease liver transplantation is the only curative treatment. Patients with liver cirrhosis caused by for example viral hepatitis, auto-immune liver diseases (AIH/PSC/PBC) or alcohol, patients with hepatocellular carcinoma or perihilar cholangiocarcinoma and patients with acute (on chronic) liver failure can be eligible for liver transplantation. The outcomes of liver transplantation have improved over the past decades with a current 1 year survival >90% and a 10 year survival >60%.

​

Research focusses on expanding the donor pool and optimization of the outcomes in liver transplantation, by performing studies on optimization of immunosuppression and recurrence of liver disease and the role of liver transplantation in Acute on Chronic Liver Failure.

The studies that are being conducted and are coordinated by the SLO are aimed at:

  • New immunosuppressive regimes

  • Optimizing the screening and selection for liver transplantation

  • Optimizing long term outcomes after liver transplantation

  • Liver transplantation for Acute on Chronic Liver Failure

 

References: 

  1. High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. Mulder MB, van der Eijk AA, Geurts van Kessel CH, Erler NS, de Winter BCM, Polak WG, Metselaar HJ, den Hoed CM. Gut. 2022 Jan 31:gutjnl-2021-326755. doi: 10.1136

  2. Recurrence of primary sclerosing cholangitis after liver transplantation - analysing the European Liver Transplant Registry and beyond. Visseren T, Erler NS, Polak WG, Adam R, Karam V, Vondran FWR, Ericzon BG, Thorburn D, IJzermans JNM, Paul A, van der Heide F, Taimr P, Nemec P, Pirenne J, Romagnoli R, Metselaar HJ, Darwish Murad S; European Liver and Intestine Transplantation Association (ELITA).Transpl Int. 2021 Aug;34(8):1455-1467. doi: 10.1111/tri.13925.

  3. Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study. Mulder MB, Borgsteede SD, Darwish Murad S, Landman CS, Metselaar HJ, Hunfeld NGM. Front Pharmacol. 2021 Apr 27;12:637090. doi: 10.3389/fphar.2021.637090. eCollection 2021.

  4. The Yield and Safety of Screening Colonoscopy in Patients Evaluated for Liver Transplantation. Oey RC, van Tilburg L, Erler NS, Metselaar HJ, Spaander MCW, van Buuren HR, de Man RA. Hepatology. 2019 Jun;69(6):2598-2607. doi: 10.1002/hep.30562. Epub 2019 Apr 6.

  5. External Validation of the RETREAT Score for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation. van Hooff MC, Sonneveld MJ, Ijzermans JN, Doukas M, Sprengers D, Metselaar HJ, den Hoed CM, de Man RA.Cancers (Basel). 2022 Jan 27;14(3):630. doi: 10.3390/cancers14030630.

bottom of page